We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Litmus test

13 August 2020 By Neil Unmack

Thermo Fisher Scientific scrapped a bid for German diagnostics group Qiagen after investors balked. The takeover was tabled in March, but the offer looked low once Covid-19 hopes boosted testing groups’ valuations. The U.S. company’s retreat suggests insiders are less gung-ho.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)